MARKET

XENE

XENE

Xenon Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.20
+0.20
+1.11%
Opening 11:23 06/24 EDT
OPEN
18.06
PREV CLOSE
18.00
HIGH
18.21
LOW
18.01
VOLUME
4.72K
TURNOVER
--
52 WEEK HIGH
21.94
52 WEEK LOW
9.32
MARKET CAP
745.60M
P/E (TTM)
-18.0305
1D
5D
1M
3M
1Y
5Y
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 06/15 11:50
Looking Into Xenon Pharmaceuticals's Return On Capital Employed
During Q1, Xenon Pharmaceuticals's (NASDAQ:XENE) reported sales totaled $4.36 million. Despite a 24.27% in earnings, the company posted a loss of $16.06 million. In Q4, Xenon Pharmaceuticals brought in $5.15 million in sales but lost $12.92 million in earn...
Benzinga · 06/04 14:49
Xenon Pharma Names Ian Mortimer as New Chief Executive Officer
MT Newswires · 06/04 06:34
Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders (the "Annual Meeting") held today on June 3, 2021.
GlobeNewswire · 06/03 21:45
Insider Trends: Insider at Xenon Pharmaceuticals Converts/Exercises Derivative Security, Sells for Taxes and Self, Buying Trend Remains Intact
MT Newswires · 06/01 16:14
Xenon Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will participate in the following investor conference:
GlobeNewswire · 05/31 20:01
Needham Maintains Their Buy Rating on Xenon (XENE)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Xenon (XENE), with a price target of $25.00. The company's shares
SmarterAnalyst · 05/12 11:45
8-K: Xenon Pharmaceuticals Inc.
(EDGAR Online via COMTEX) -- false 0001582313 0001582313 2021-05-11 2021-05-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/12 00:48
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XENE. Analyze the recent business situations of Xenon Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XENE stock price target is 26.88 with a high estimate of 31.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 35.85M
% Owned: 87.52%
Shares Outstanding: 40.97M
TypeInstitutionsShares
Increased
33
4.03M
New
14
1.69M
Decreased
24
715.46K
Sold Out
4
48.95K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.46%
Pharmaceuticals & Medical Research
+1.05%
Key Executives
Non-Executive Chairman/Independent Director
Michael Tarnow
President/Chief Executive Officer/Chief Operating Officer
Ian Mortimer
Chairman/Executive Director
Simon Pimstone
Executive Vice President
Robin Sherrington
Senior Vice President/Director of Human Resources
Shelley McCloskey
Senior Vice President
James Empfield
Chief Financial Officer
Sherry Aulin
Other
Ernesto Aycardi
Director
Patrick Machado
Independent Director
Mohammad Azab
Independent Director
Clarissa Desjardins
Independent Director
Steven Gannon
Independent Director
Michael Hayden
Independent Director
Frank Holler
Independent Director
Gary Patou
Independent Director
Dawn Svoronos
No Data
About XENE
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

Webull offers kinds of Xenon Pharmaceuticals Inc stock information, including NASDAQ:XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.